INTRODUCTION
Currently, it is estimated that diabetes mellitus affects more than 150 million people worldwide (Engelgau et al., 2003) ; moreover, this number is expected to increase to approximately 300 million by 2025 (Zimmet et al., 2001 Permutt et al., 2005) .
Diabetic patients display numerous diabetic complications (e.g., retinopathy, nephropathy and neurosis) dependent on the extent of the damage caused by disease progression; furthermore, these individuals are threatened by complications leading to cardiovascular damage (Gillies and Su, 1993; Stockand and Sansom, 1997) . Diabetic bladder dysfunction is among the most common and costly consequences of diabetes; dysfunctions include decreased bladder sensation, increased bladder capacity and impaired bladder emptying with resultant increased post-void residual urine. As a result, urinary incontinence in the diabetic patient has been most commonly attributed to over-flow incontinence as a sign of voiding problems. Estimates of the prevalence of dysfunction range from 25-85% (Starer and Libow, 1990; Ueda et al., 1997; Brown et al., 2005) . While this condition is not life-threatening, it is associated with several debilitating symptoms, which disrupt patient quality of life. However, therapy for diabetic bladder dysfunctions has not been established.
Assessment of bladder smooth muscle contractility is important in terms of
understanding the mechanisms governing diabetic dysfunctions due to the involvement of neuronal dysfunction in diabetes (Poladia and Bauer, 2005) . Alterations of contractile responses have been documented and correlations between receptor activity and/or intracellular signaling pathways have been suggested in various types of smooth JPET #144907 -6 -muscle tissues isolated from diabetic models (Arun et al., 2005; Schulingkamp et al., 2005; Ma et al., 2008) . We have also reported increased vascular smooth muscle contraction in a type-II diabetic mouse model (Nobe et al., 2002; Nobe et al., 2003a ).
This increased contraction was enhanced under high-glucose (HG) conditions (Nobe et al., 2004) . Moreover, spontaneous contraction in diabetic portal vein lacked extracellular glucose-dependency. Therefore, we suggested that both diabetic dysfunction and extracellular glucose-dependency might be responsible for various patterns of changes in each smooth muscle tissue. Increased carbachol (CCh)-induced contraction was demonstrated in bladder smooth muscle in streptozotocin-induced diabetic rat (Yang et al., 2007) ; in contrast, reduced contraction was noted in combined hypertensive and hyperlipidemic rat (Nobe et al., 2008) . Extracellular glucose-dependencies have not been evaluated in these bladder dysfunctions. Based on these findings, we hypothesized that detection of bladder smooth muscle dysfunctions and elucidation of the underlying mechanisms under normal and HG conditions are essential in order to establish novel therapeutic regimes in diabetic patients.
The objective of this study was to identify alterations of contractile responses and intracellular mechanisms in bladder smooth muscle tissue isolated from type-II diabetic mouse models under normal and HG conditions.
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Methods
Reagents. Carbachol (CCh), atropine sulfate (Atr) and 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo-(2,3-α)pyrrolo(3,4-+-c)-carbazole (Gö6976) were obtained from Sigma-Aldrich (St. Louis, MO). added to increase the solubility of fura-PE3/AM. Tissues were incubated at room temperature for 5-6 hr, after which they were rinsed in 37 o C PSS for 15 min to remove free dye. Subsequently, bladder strips were mounted in a measurement chamber.
1-(5-isoquinolinesulfonyl)homopiperazine
One end of the tissue was connected to the force transducer and the other end was fixed to the front-surface fluorimeter (CAM-230, Japan Spectroscopic Co., Tokyo). Resting tension was set at 10 mN, where the tissue length was established to be in the optimal range for force generation. The chamber was placed in the holder (water-jacketed, 37 o C) of the CAM-230 dual wavelength spectrofluorimeter. Fluorescence was excited at 340 and 380 nm, and emission was measured at 510 nm. As previously described, the This article has not been copyedited and formatted. The final version may differ from this version. ] i (nM) as reported by Grynkiewicz et al.
( Grynkiewicz et al., 1985) . Ionomycin (10 µM) and Ca
2+
-EGTA solutions were used to establish R min and R max ; furthermore, Mn 2+ served to quench the fura-PE3
fluorescence for the background fluorescence of the bladder; the Kd value was set at 224 nM.
Measurement of PKC Activity. Fresh tissues were treated under various conditions and then homogenized with a polytrone homogenizer in 0.5 mL of ice-cold solution consisting of 20 mM 3-(N-morpholino)propane sulfonic acid (pH 7.2), 250 mM sucrose, 1 mM dithiothreitol, 1 mM EGTA, 1 µg/mL pepstatin, 1 µg/mL leupeptin and 50 µg/mL trypsin inhibitor (Buffer A). The homogenates were centrifuged
(1,000xg for 5 min) to remove the nuclei. Supernatants were decanted and pellets were washed once with Buffer B (sucrose-free Buffer A). The combined supernatants were centrifuged a second time (2,000xg for 30 min). Finally, the membrane and cytosol fractions were collected by centrifugation (100,000xg for 60 min). PKC activity was measured using the PepTag Protein Kinase Assay (Promega, Madison, WI).
The assay is based on the highly specific phosphorylation of a fluorescent PepTag C1 peptide substrate by PKC. Collected fractions (2.5 µg protein/mL) were incubated with 2 µg of PepTag, a PKC substrate, and a PKC activating solution (phosphatidyl serine, 5 µg) for 30 min at 30°C. The reaction was terminated by boiling the assay medium in a water bath for 10 min. The samples were further electrophoresed on an Figure 1A and 1B; the averaged concentration-response relationships from these experiments for both bladder types are summarized in Figure   1C . The submaximal increase in force response in C57Bl mouse bladder in the presence of 30 µM CCh was 12.69 ± 0.22 mN/mm 2 (n = 8). At higher CCh levels, force development declined. In the ob/ob mouse, the maximal increase in isometric This article has not been copyedited and formatted. The final version may differ from this version. In order to demonstrate alteration of bladder contractility in hyperglycemia,
CCh-induced changes in isometric force development were measured under HG conditions. Diabetes, which is characterized by elevated extracellular glucose levels, was created by pretreatment of the bladder with HG-PSS at 37 o C for 30 min. This condition was introduced in our previous studies (Nobe et al., 2003b; Nobe et al., 2004) .
Prior to measurements under HG conditions, several basic factors were examined in the current investigation. We confirmed that the effects of 2-fold HG-PSS were submaximal and that these effects did not differ from those in 3-and 4-fold HG-PSS.
Moreover, the HG-PSS effects were time-and dose-dependent and a 30 min pretreatment period was submaximal. Over-night incubation of tissues under HG conditions led to similar responses in comparison to 30 min pretreatment (data not shown).
In order to evaluate the effect of osmotic changes under HG conditions, 11.1 mM sucrose was added to normal-PSS. However, this sucrose-supplemented (total, 22. The muscarinic receptor antagonist atropine (Atr; 3, 10, 30, 100 and 300 nM, 10 min pre-incubation) inhibited the CCh-induced increase in isometric force in C57Bl and ob/ob mice. In C57Bl mouse bladder, dose-response curves were shifted to higher concentrations of CCh (data not shown). Similar responses were detected under HG conditions. pA 2 values of Atr in normal-and HG-PSS were 9.27 and 9.26, respectively.
Under normal and HG conditions, CCh-induced dose-response curves in the ob/ob mouse were also shifted to higher concentrations of CCh. Differences between normal and HG conditions remained in the presence of Atr. pA 2 values of Atr in normal-and HG-PSS were 9.14 and 9.30, respectively.
Effects of Calcium Channel Antagonist on CCh-induced Increase in Isometric
Force in C57Bl and ob/ob Mouse Bladders.
In order to identify an association between calcium channel activity and the enhancement of force development in ob/ob mouse, the voltage-dependent calcium 
Relationship between [Ca

2+
] i and isometric force development in C57Bl and ob/ob mouse bladder. CCh-induced dose-dependent increases in force developments were detected in fura-PE3-loaded bladder as in Figure 1 . During the measurements, ] i level at each CCh concentration could not be distinguished from the corresponding level in normal-PSS.
Effects of PKC Inhibitors on CCh-induced Bladder Contractility under HG
Conditions in C57Bl and ob/ob Mice. In order to identify a relationship between PKC and bladder contraction in C57Bl and ob/ob mice, three types of PKC inhibitors were introduced. Calphostin C is a general-type (non-isoform-specific type) PKC inhibitor. Gö6976 and rottlerin, a calcium-dependent and -independent PKC inhibitor, respectively, were selected (Fig. 4) . To assess the specific inhibitory effects of the aforementioned PKC inhibitors, time-and dose-dependencies of these agents were measured (data not shown). Based on these preliminary trials, each condition was activities in the presence or absence of CCh. In ob/ob mouse, a CCh-induced increase in rho A activity was detected (1139.3 ± 125.1 RLU; n = 5); furthermore, the activity was higher than that in C57Bl mouse. Under HG conditions, significant enhancement of rho A activities relative to those values in normal-PSS were evident not only in bladders following treatment with CCh (1633.5 ± 100.4 RLU; n = 5) but also during the non-stimulated resting state (436.7 ± 51.6 RLU; n = 5). Significant differences between C57Bl and ob/ob mice were also observed under HG conditions. The rho A activities were apparently reduced by pretreatment of bladder tissues with the rho inhibitor, C3-exoenzyme (10 µg/mL, 5 hr; data not shown).
In the C57Bl mouse, pretreatment with 1 µM fasudil significantly reduced the isometric force attributable to CCh; moreover, the resting level was unaffected (Fig. 6 ).
Isometric force induced by 30 µM CCh in the presence of fasudil was 3.55 ± 0.16 mN/mm 2 (14.3% of the control response; n = 5). A similar inhibitory effect of fasudil was evident in ob/ob mouse bladder. Dose-response curves for CCh in the presence of fasudil in C57Bl and ob/ob mice overlapped (Fig. 6C) . Differences between C57Bl
and ob/ob mice were suppressed by fasudil pretreatment. Enhanced ob/ob mouse bladder contraction under HG conditions was inhibited and differences between normaland HG-PSS were also suppressed by fasudil treatment. Inhibitory effects on the ob/ob mouse bladder similar to those of fasudil were detected following application of another type of rho kinase inhibitor, namely, Y27632 (data not shown). 
Alteration of Total
Discussion
This study revealed the amplification of enhanced contraction in diabetic mouse bladder under HG conditions. Moreover, involvement of the rho A-rho kinase-regulated nPKC pathway in the dysfunction was suggested.
Experimental diabetic models were employed in a variety of studies (Yono (Table 2) . Frequent urination and dysuria, which are typical diabetic dysfunctions, might be associated with the symptoms including alteration of bladder smooth muscle contraction. Therefore, we surmised that analysis of contractile dysfunctions in ob/ob mouse bladder could elucidate mechanisms underlying urinary complications in diabetic patients.
CCh-induced bladder smooth muscle contraction displayed significant enhancement in ob/ob mice (Fig. 1) . Increases in bladder contraction have also been reported in streptozotocin-induced type-I diabetic rat (Yang et al., 2007) . According to these reports, CCh-induced maximal responses were 120-140% of normal responses.
Our results were consistent with those obtained in the aforementioned animals. These in ob/ob mice leads to serious urinary dysfunction due to enhancement of total urine volume ( Table 2 ). The ob/ob mouse indicated sustained hyperglycemia (Table 1) ;
consequently, the effect of extracellular glucose level on CCh-induced bladder contraction was assessed in this investigation. Based on the fasting plasma glucose level in the ob/ob mouse (Table 1) , glucose at twice the normal extracellular glucose concentration (22.2 mM) served as the HG condition. The current HG condition consisted of only 30 min HG-PSS treatment; however, we believed that this condition was an excellent approximation of diabetic hyperglycemia. The veracity of the aforementioned HG condition was supported by our preliminary trials in terms of glucose concentration (11.1-44.4 mM) and pretreatment period (10 min-12 hr)
dependencies. Under HG conditions, significant enhancement of bladder contraction was detected solely in the ob/ob mouse (Fig. 1) . Procurement of glucose dependency in diabetic bladder contraction was described initially in this study. Our findings indicated that bladder contraction increases in diabetes and that increased contraction is enhanced in hyperglycemia. Accordingly, aggravation of bladder dysfunction in hyperglycemia was suggested. and ob/ob mice; although inhibitory rates were similar, differences between these types of mice were observed (Fig. 2) . These data suggested that the meaningful increase in bladder contraction in ob/ob mice was not derived from increased activation of calcium channels.
Based on these results, we surmised that alteration of both muscarinic receptors and calcium channels do not play a major role in enhanced contraction in ob/ob mouse bladder. The relationship between [Ca 2+ ] i and force development, as intracellular calcium sensitivity of bladder contraction, was examined in order to develop an understanding of the mechanism (Fig. 3) . Developed force levels in ob/ob mouse bladder were significantly enhanced relative to those of the C57Bl mouse at similar [Ca 2+ ] i levels. This finding was indicative of enhancement of calcium sensitivity in diabetic bladder contraction. Enhanced calcium sensitivity was also reported in other diabetic models (Waring and Wendt, 2000) . Details regarding sensitization are poorly understood; moreover, an increase in myosin light chain phosphorylation associated with calcium sensitization was suggested.
This study focused on the enhancement of calcium sensitization in ob/ob mouse bladder under HG conditions (Fig. 3) . During sensitization, CCh-induced alteration of (cPKC; PKC-α, β-II and γ) and -independent (nPKC; PKC-δ, ε, η and θ) isoforms (Das Evcimen and King, 2007 ).
An inhibitor of cPKC, Gö6976, altered CCh-induced contraction only in C57Bl mouse (Fig. 4A) . In contrast, extracellular glucose-dependent enhancement of contraction in ob/ob mouse was unaffected (Fig. 4B) . These results indicated that the glucose-dependent enhancement of bladder contraction is not involved in calcium-dependent PKC activation; therefore, activation of the calcium-dependent pathway might not contribute to the enhancement of ob/ob mouse bladder contraction.
Rather, rottlerin, a nPKC inhibitor, significantly reduced CCh-induced bladder contraction (Fig. 4) and total PKC activity (Fig. 7) in ob/ob mouse. These findings indicated that nPKC plays a role in diabetic mouse bladder dysfunction. Interestingly, extracellular glucose-dependent enhancement of contraction and PKC activation in the ob/ob mouse were also suppressed by rottlerin. These results suggested that diabetic mouse bladder dysfunction is regulated by nPKC and that glucose-dependent enhanced contraction is derived from increased activation of nPKC without affecting the intracellular calcium level.
A typical pathway, namely, rho and the rho kinase pathway, which is involved in vascular and intestinal smooth muscle contractions, was examined to confirm the participation of the calcium-independent signaling pathway. C57Bl mouse (Fig. 5) . Extracellular glucose-dependent enhancement of rho A activities was detected exclusively in ob/ob mouse bladder. These patterns of changes were well correlated with the alteration of ob/ob mouse bladder contraction under HG conditions (Fig. 1C) . Moreover, the rho kinase inhibitor, fasudil, significantly inhibited CCh-induced bladder contraction in both types of mice (Fig. 6) .
Enhancement of contraction in the ob/ob mouse under normal and HG conditions was also suppressed in the presence of fasudil. These data indicated that the increased rho A activity in ob/ob mouse led to enhancement of rho kinase activity. Therefore, differences in contraction between C57Bl and ob/ob mouse bladders might be associated with over-activation of the rho A-rho kinase pathway. Results of PKC-and rho kinase-inhibitor treatments (Fig. 4, 6 ) suggested that the rho A-rho kinase-mediated calcium-independent pathway might play an essential role in diabetic bladder contraction.
How is diabetic bladder dysfunction regulated by both the rho A-rho kinase and nPKC pathways? A relationship between PKCδ (a member of the nPKC sub-family) and rho kinase was suggested by some researchers (Kandabashi et al., 2003; Li et al., 2005) . In cerebral artery, rho and the rho kinase pathway activate the PKCδ isoform (Obara et al., 2005) , which induces enhancement of vascular contraction and is caused by cerebral vasospasm. In a manner similar to the calcium-independent signaling pathway, we hypothesized that glucose-dependent enhancement of contraction is also involved in the regulation of PKCδ via the rho A-rho kinase pathway. Fasudil-induced rho kinase inhibition attenuated PKC activity (Fig. 7B) , which supports this hypothesis.
This article has not been copyedited and formatted. The final version may differ from this version. ] i and isometric force were measured simultaneously as described in Methods. Water intake and urine volume were measured in 16-week-old C57Bl and ob/ob mice using the individual cage system as described in "Methods". * p<0.01 vs C57Bl mouse (t-test). 
